Predicting emergence of levodopa induced dyskinesia in parkinson’s disease by a brain imaging based biomarker.
Loading...
Date
2017
Authors
Aljuaid, Maram
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
The forefront treatment of Parkinson’s disease (PD) is levodopa. Previously, it has been reported that cerebral blood flow is increased while neuronal activity is decreased in key subcortical regions including the putamen when patients are treated with levodopa. This may be associated with levodopa-induced dyskinesia (LID). To study the effect of clinically-determined anti-parkinsonian medication, ten PD patients (5 with LID and 5 without LID) have been scanned with [18F]-fluorodeoxyglucose PET (FDG-PET) and perfusion MRI (pMRI) when they are ON and OFF medication. Regions of interest were defined and mean values were calculated. A significant interaction effect has been found in the putamen (p=0.023). This dissociation was especially predominant in patients with LID compared to the ones without. We proposed a novel analytical method to quantify the degree of dissociation in the putamen, Putamen-to-thalamus Hyperperfusion/hypometabolism Index (PHI), which may have potential to be used as a biomarker for LID.
Description
Keywords
cerebral blood flow, glucose metabolism, magnetic resonance imaging, neurovascular coupling hypothesis, positron emission tomography